Drug retailing gives Unichem extra boost
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.UNICHEM, the drugs wholesaler and retailer, has increased pre-tax profits by 55 per cent for the half-year to 30 June.
The impressive performance derives from Unichem's exposure to recession-resistant prescription pharmaceuticals and its increased interest in drug retailing.
Unichem said it had about a 30 per cent share of pharmaceutical wholesaling in Britain. Its sales and profits from over-the-counter products such as toiletries were flat but sales of prescription drugs continued to flourish.
Unichem sold more drugs because the ageing British population is demanding more. Manufacturers such as Glaxo are also producing more expensive drugs.
Unichem had 162 retail pharmacies on 30 June, up from 132 the year before. It now has 196 outlets.
The results were marred by a pounds 2.5m extraordinary charge against the closure of Unichem's nappy manufacturing operation, Neptune.
Earnings per share were 7.2p, up from 6p, and the dividend was raised from 1.65p to 1.9p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments